Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26058916 | 0.80 | NAMPT (0.41) | CA2CA1NAMPTHTTGABRA1 | |
| SCHEMBL25673267 | 0.79 | CA2 (0.52) | CA2TSHRGABRA1GABRB2ALDH1A1 | |
| SCHEMBL819594 | 0.79 | CA1 (0.50) | CA2CA1TSHRHTTMAP2K1 | |
| SCHEMBL29973162 | 0.79 | CA1 (0.50) | CA2CA1TSHRHTTMAP2K1 | |
| SCHEMBL179312 | 0.77 | TSHR (0.50) | CA2CA1TSHRNAMPTHTT | |
| SCHEMBL10338061 | 0.77 | TSHR (0.50) | CA2CA1TSHRHTTMAP2K1 | |
| Hydrogen Sulfide SCHEMBL29288364 | 0.77 | CA1 (0.48) | CA2CA1TSHRHTTMAP2K1 | |
| SCHEMBL13209347 | 0.76 | CA2 (0.41) | CA2CA1TSHRNAMPTHTT | |
| SCHEMBL11955160 | 0.76 | TSHR (0.45) | CA2TSHRNAMPTHTTGABRA1 | |
| SCHEMBL1395550 | 0.76 | CA2 (0.41) | CA2CA1TSHRNAMPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230143938-A1 | PYRAZOLOQUINOLINE KRAS INHIBITORS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143938-A1 | PYRAZOLOQUINOLINE KRAS INHIBITORS | KRAS, NRAS, HRAS | CA2 3724/4885CA1 4281/4885TSHR 4583/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | CA2 2485/4885CA1 2663/4885TSHR 4045/4885 |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | KRAS, FGFR2, FGFR3 | CA2 3719/4885CA1 4563/4885TSHR 3385/4885 |
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | KRAS, NRAS, HRAS | CA2 3724/4885CA1 4281/4885TSHR 4583/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CA2 3406/4885CA1 4463/4885TSHR 3876/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | CA2 3488/4885CA1 3455/4885TSHR 3862/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | CA2 3517/4885CA1 4041/4885TSHR 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.